SD

Sudipta Das

Active Director Director DIN 08824761
DIN 08824761 First appointment Aug 2020 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2020
Shareholding value •••• Premium profile

About Sudipta Das

Data last updated:

Sudipta Das is a Director at Own-Med Pharmaceutical Private Limited (since 2020). The company operates in Pharma. Own-Med Pharmaceutical Private Limited reported revenue of ₹20,500 (FY 2021).

DIN 08824761
Primary Designation Director
Industry Pharma
First Appointment 06 Aug 2020
Oldest Company Age 6 yrs
Largest company Own-Med Pharmaceutical Private Limited · ₹20,500 (FY 2021)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director06 Aug 20202020₹20,500 (FY 2021)Active

Directorship timeline

Open interactive timeline →
Own-Med Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Sudipta Das

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sudipta Das

Sudipta Das currently holds 1 directorship: Own-Med Pharmaceutical Private Limited (Director, since 06 Aug 2020, revenue ₹20,500 (FY 2021)).

Sudipta Das was first appointed on 06 Aug 2020 as Director at Own-Med Pharmaceutical Private Limited.

The current boards of Sudipta Das's companies include Arabinda Dey (Own-Med Pharmaceutical Private Limited), Pratyus Chakraborty (Own-Med Pharmaceutical Private Limited), Sabir Ali Middya (Own-Med Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available